TABLE 2

Observed Versus Expected Numbers of Deaths in Each TNM Stage for Various Follow-up Periods

Value for stage*:
Follow-upParameterI (1,577)II (306)III (300)IVA (95)IVC (150)
5 yO131119638
E27.011.513.75.414.0
SMR for O/E (95% CI)0.48 (0.26–0.89)0.96 (0.49–1.86)1.39 (0.84–2.31)1.11 (0.46–2.69)2.72 (1.90–3.91)
P0.0070.8870.1490.801<0.001
10 yO3424241056
E51.322.724.79.722.0
SMR for O/E (95% CI)0.66 (0.45–0.97)1.06 (0.67–1.66)0.97 (0.62–1.53)1.03 (0.51–2.06)2.54 (1.89–3.42)
P0.0160.7860.8850.924<0.001
15 yO4532291269
E69.631.631.911.226.6
SMR for O/E (95% CI)0.65 (0.46–0.90)1.01 (0.68–1.50)0.91 (0.60–1.38)1.07 (0.57–2.03)2.59 (1.98–3.39)
P0.0030.9360.6130.810<0.001
20 yO5137321473
E79.936.935.412.029.1
SMR for O/E (95% CI)0.64 (0.47–0.87)1.0 (0.7–1.45)0.9 (0.61–1.34)1.16 (0.65–2.10)2.51 (1.93–3.26)
P0.0010.9830.5710.569<0.001
MaximumO5238331475
E84.740.335.812.130.7
SMR for O/E (95% CI)0.61 (0.45–0.84)0.94 (0.66–1.35)0.92 (0.63–1.36)1.16 (0.64–2.10)2.45 (1.89–3.17)
P<0.0010.7130.6400.576<0.001
  • * Values in parentheses are numbers of patients.

  • O = observed number of deaths in population of patients with DTC; E = expected number of deaths in matched population.